Clinical trials: Liver Disease Chronic
Hepatitis C Virus
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
The objectives of this study are to collect and assess data related to safety and effectiveness of Sovaldi treatment regimens, per the approved prescribing information for Sovaldi, in routine clinical practice and report results…
- Trial name
- NCT02907996
- Testing
- Sofosbuvir
- Where
- 72 sites in South Korea
- Volunteers
- 2,033 people
- Sponsor
- Gilead Sciences
Liver Failure, Acute on Chronic
Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure
Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure
- Trial name
- NCT03863002
- Testing
- Mesenchymal Stem Cell
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Tianjin Weikai Bioeng., Ltd.
Drug-induced Liver Injury, Autoimmune Hepatitis
Discrimination of DILI and AIH by Artificial Intelligence
A retrospective, multi-center, non-interventional cohort study has been going to explore whether artificial intelligence can discriminate Drug-induced liver injury and Autoimmune hepatitis.
- Trial name
- NCT05532345
- Where
- China
- Volunteers
- 2,583 people
- Sponsor
- Beijing Friendship Hospital
Hepatitis B, Chronic
Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B
The purpose of this study is to compare the effectiveness of entecavir plus tenofovir combination therapy with that of entecavir monotherapy. Safety will also be studied.
- Trial name
- NCT00410072
- Testing
- Entecavir, Entecavir + Tenofovir
- Where
- 68 sites in United States, Argentina and 11 more
- Volunteers
- 669 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease, Late Onset, Stroke
Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care
Since September 1st, 2009, Taiwan has begun to pay attention to the care of patients with organ failure, dementia and the elderly, and brought eight of non-cancer terminal patients into health insurance subsidies to implement the…
- Conditions
- Alzheimer Disease, Late Onset, Stroke, Heart Failure, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT05407272
- Testing
- Health Education Manual, manual
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wen-Shiou Pan
Chronic Hepatitis C, Fibrosis
Combination Drug Therapy for Patients With Hepatitis C
Hepatitis C is a major cause of liver disease in the United States and leads to cirrhosis of the liver in approximately one-third of patients some of whom will ultimately suffer from liver failure or liver cancer.
- Conditions
- Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
- Trial name
- NCT00001729
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
The primary objective of the PK Lead-in Phase of the study is to evaluate the steady state pharmacokinetics (PK) and confirm the dose of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) in hepatitis C virus…
- Trial name
- NCT02249182
- Testing
- LDV/SOF, RBV
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 226 people
- Sponsor
- Gilead Sciences
Autoimmune Hepatitis, Autoimmune Liver Disease
PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
The investigators identified polyreactive immunoglobulin G (pIgG) in adults (published in Hepatology: https://doi.org/10.1002/hep.32134) and children (in preparation).
- Trial name
- PIONEER (NCT05810480)
- Testing
- polyreactive immunoglobulin G
- Where
- 6 sites in Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Hannover Medical School
Hepatitis B, Chronic
A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
HBV(hepatitis B virus) with metabolic comorbidities may accelerate liver disease progression and increase the risk of HCC(Hepatocellular Carcinoma)development.
- Trial name
- NCT05057065
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Hong Ren
Chronic Hepatitis c
DAA Therapy in Pediatric Patients With Chronic Hepatitis C
The Mukh-Mantri Punjab Hepatitis C Relief Fund (MMPHCRF) is a public health initiative for prevention and control of hepatitis C in the Punjab state, India.
- Trial name
- NCT03481036
- Testing
- Direct Acting Antivirals, DAAs in Cirrhotics Genotype 2/3, DAAs in Cirrhotics Genotye 1,4,5,6
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatitis C, Chronic, Hepatitis C
Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)
The objective of the study is to evaluate, in each group, the number of participants who achieve rapid virological response (RVR) after 4 weeks treatment with PegIntron and Rebetol.
- Trial name
- APEGIN (NCT00724854)
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 1,146 people
- Sponsor
- Merck Sharp & Dohme LLC
Intestinal Microbiota Between Different Groups
Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases
The recent introduction of direct-acting antiviral (DAA) therapy has dramatically changed the rates of cure of HCV infection even in difficult to treat subjects and in those with severe comorbidities .
- Trial name
- NCT06829966
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie
Chronic Liver Disease
Observational Clinical Study of the Natural Course and Long-term Prognosis of Patients With Chronic Liver Disease
Chronic liver disease is a global public health problem. Without timely diagnosis and treatment, chronic liver disease can progress to hepatitis, liver fibrosis, and cirrhosis, while causing a variety of complications such as…
- Trial name
- NCT05653830
- Where
- China
- Volunteers
- 50,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepatitis B, Acute-On-Chronic Liver Failure
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.
- Trial name
- HBV (NCT03920618)
- Testing
- Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Growth Failure, Chronic Liver Disease
Increlex Treatment of Children With Chronic Liver Disease and Short Stature
A major consequence of chronic liver disease in childhood is growth failure. This is because a chemical essential for growth called growth factor is created in the liver.
- Trial name
- NCT01314508
- Testing
- Increlex
- Sponsor
- University of California, Los Angeles
Chronic Hepatitis B
A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine
The purpose of this clinical research study is to assess the safety and effectiveness of switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.
- Trial name
- NCT00036608
- Testing
- Entecavir
- Where
- 39 sites in United States
- Sponsor
- Bristol-Myers Squibb
Urea Cycle Disorder
Chronic Liver Disease in Urea Cycle Disorders
This is a pilot, cross-sectional study to assess liver stiffness and markers of hepatic injury, function, and fibrosis in patients with urea cycle disorders.
- Trial name
- NCT03721367
- Testing
- Diagnostic Ultrasound
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Baylor College of Medicine
Hepatitis C
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
Post-marketing surveillance study to evaluate the real world safety and effectiveness of Maviret (Glecaprevir/Pibrentasvir) administered under a normal, routine treatment practice by Korean patients with Chronic Hepatitis C…
- Trial name
- Maviret PMS (NCT03740230)
- Where
- 61 sites in South Korea
- Volunteers
- 3,134 people
- Sponsor
- AbbVie
Hepatitis B Virus Infection, Children
Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B
This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-tolerant, HBeAg-positive children aged 3-6 years with…
- Conditions
- Hepatitis B Virus Infection, Children, Chronic Hepatitis B
- Trial name
- NCT07345624
- Testing
- Entecavir, Entecavir + Pegylated interferon α-2b
- Volunteers
- 80 people
- Sponsor
- Qing-Lei Zeng